What is Erytech Pharma?
ERYTECH is a biopharmaceutical firm dedicated to pioneering novel red blood cell-based therapeutics for severe cancers and rare diseases. The company's proprietary ERYCAPS® platform facilitates the encapsulation of drug substances within red blood cells, enabling the development of a robust pipeline. ERYTECH's strategic focus is on creating product candidates that disrupt the metabolic pathways of cancer cells by limiting their access to essential amino acids, thereby inhibiting growth and survival. Established in 2004 and based in Lyon, France, ERYTECH is at the forefront of innovative oncology treatments.
How much funding has Erytech Pharma raised?
Erytech Pharma has raised a total of $23.1M across 1 funding round:
Stock Offering
$23.1M
Stock Issuance/Offering (2013): $23.1M, investors not publicly disclosed
What's next for Erytech Pharma?
The substantial enterprise-level funding and recent strategic investment indicate Erytech Pharma's advanced stage of development and its potential for significant market impact. This capital infusion is expected to accelerate the clinical development of its pipeline, potentially bringing its innovative red blood cell-based therapeutics closer to patients with high unmet medical needs. The company's focus on targeting cancer cell metabolism positions it as a key player in the evolving landscape of oncology treatments, with future growth likely centered on advancing its lead candidates through further clinical trials and regulatory approvals.
See full Erytech Pharma company page
